徐放性賦形剤の市場規模、シェア、成長分析：タイプ別、技術別、投与経路別、地域別 - 産業予測 2025～2032年

徐放性賦形剤市場規模は2023年に16億米ドルと評価され、2024年の17億3,000万米ドルから2032年には32億3,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは8.1%で成長する見通しです。

世界の徐放性賦形剤市場は、慢性疾患の有病率の上昇と革新的なドラッグデリバリーシステムに対する需要の高まりに後押しされ、力強い成長を遂げています。徐放性製剤は薬物を徐々に放出させるため、患者のコンプライアンスと治療効果を高め、様々な剤形において賦形剤が不可欠となっています。新規ポリマーやコーティングを含む賦形剤技術の最近の進歩は、利用可能な製剤の選択肢を広げています。多国籍企業から専門企業まで、主要企業は積極的に研究に投資し、カスタマイズされた製剤を生み出すためにパートナーシップを結んでいます。北米と欧州が市場をリードする一方で、アジア太平洋やラテンアメリカなどの新興地域も急速に拡大しています。精密医療と個別化治療に焦点が当てられ、洗練された賦形剤ソリューションの需要が高まっていることから、将来は明るいと思われます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ

徐放性賦形剤市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• ゼラチン
• ポリマー
• ミネラル
• 糖類
• その他

徐放性賦形剤市場規模：技術別& CAGR（2025-2032）

• 市場概要
• ターゲットデリバリー
• マイクロカプセル化
• ウルスターテクニック
• その他

徐放性賦形剤市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 筋肉内
• 皮下
• 経皮
• 静脈
• その他

徐放性賦形剤市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• International Flavors & Fragrances Inc.（United States）
• Evonik Industries AG（Germany）
• BASF SE（Germany）
• Kerry Group Plc（Ireland）
• Roquette Freres（France）
• Merck KGaA（Germany）
• Associated British Foods Plc（United Kingdom）
• ADM（United States）
• Wacker Chemie AG（Germany）
• Croda International Plc（United Kingdom）
• Gattefosse（France）
• Colorcon Inc.（United States）
• AstraZeneca PLC（United Kingdom）
• GlaxoSmithKline PLC（United Kingdom）
• Mayne Pharma Group Limited（Australia）
• Sun Pharmaceutical Industries Ltd.（India）
• Pfizer Inc.（United States）
• Novartis AG（Switzerland）

結論と提言

Sustained Release Excipients Market size was valued at USD 1.6 billion in 2023 and is poised to grow from USD 1.73 billion in 2024 to USD 3.23 billion by 2032, growing at a CAGR of 8.1% during the forecast period (2025-2032).

The global sustained release excipients market is experiencing robust growth, fueled by a rising prevalence of chronic diseases and an increased demand for innovative drug delivery systems. As sustained release formulations facilitate gradual drug release, they enhance patient compliance and therapeutic effectiveness, making their excipients vital in various dosage forms. Recent advancements in excipient technologies, including novel polymers and coatings, broaden the formulation options available. Key players, ranging from multinational firms to specialized companies, are actively investing in research and forging partnerships to create customized formulations. While North America and Europe lead the market, emerging regions like Asia-Pacific and Latin America are also expanding rapidly. The future looks bright, with a focus on precision medicine and personalized therapies driving demand for sophisticated excipient solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Sustained Release Excipients market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Sustained Release Excipients Market Segments Analysis

Global Sustained Release Excipients Market is segmented by Type, Technology, Route of Administration and region. Based on Type, the market is segmented into Gelatin, Polymers, Minerals, Sugars and Others. Based on Technology, the market is segmented into Targeted Delivery, Microencapsulation, Wurster Technique and Others. Based on Route of Administration, the market is segmented into Oral, Intramuscular, Subcutaneous, Transdermal, Intravenous and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Sustained Release Excipients Market

The Sustained Release Excipients market is significantly influenced by the aging global population, which is reshaping demographic trends and leading to increased demand for healthcare products and pharmaceuticals. These excipients offer notable advantages, including prolonged drug release, which enhances patient compliance and is particularly beneficial for managing chronic conditions prevalent among elderly individuals. As healthcare providers seek to address the unique challenges posed by this demographic shift, the necessity for medications tailored to the needs of older patients becomes increasingly apparent. Consequently, this trend is expected to sustain a consistent demand for sustained release excipients within the pharmaceutical industry.

Restraints in the Sustained Release Excipients Market

The Sustained Release Excipients market faces significant constraints due to stringent regulations that govern drug approval and release within the pharmaceutical industry. This complex regulatory framework presents substantial challenges, as companies must navigate lengthy approval processes while ensuring compliance, resulting in high costs and time commitments. Additionally, frequent updates to regulatory standards and guidelines can lead to unforeseen delays in product development and market launch. Such obstacles not only impede the timely introduction of new products but also hinder overall market growth, making it crucial for companies to carefully manage their approaches to meet these requirements effectively.

Market Trends of the Sustained Release Excipients Market

The Sustained Release Excipients market is witnessing a significant trend towards increased focus on personalized medicine, propelled by advancements in biomarker identification and genomics. As the pharmaceutical industry pivots towards tailored therapeutics that cater to individual patient profiles, the demand for sustained release excipients is escalating. These excipients facilitate precise dosing and optimized timing of drug release, enhancing therapeutic outcomes while reducing side effects. This trend aligns with the broader shift towards patient-centric healthcare and is fostering innovation in excipient formulations and technologies, ultimately supporting the development of more effective and personalized drug delivery systems.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Sustained Release Excipients Market Size by Type & CAGR (2025-2032)

• Market Overview
• Gelatin
• Polymers
• Minerals
• Sugars
• Others

Global Sustained Release Excipients Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Targeted Delivery
• Microencapsulation
• Wurster Technique
• Others

Global Sustained Release Excipients Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intramuscular
• Subcutaneous
• Transdermal
• Intravenous
• Others

Global Sustained Release Excipients Market Size & CAGR (2025-2032)

• North America (Type, Technology, Route of Administration)
  • US
  • Canada
• Europe (Type, Technology, Route of Administration)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Technology, Route of Administration)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Technology, Route of Administration)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Technology, Route of Administration)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• International Flavors & Fragrances Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evonik Industries AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BASF SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kerry Group Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roquette Freres (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Associated British Foods Plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADM (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wacker Chemie AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Croda International Plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gattefosse (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Colorcon Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayne Pharma Group Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations